Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC28-E in Diabetic Macular Edema
NCT04782115Phase 2Completed
- Sponsor
- RemeGen
- Start
- Mar 2021
- Primary completion
- Jul 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of eflimrufusp alfa in diabetic macular edema (DME), sponsored by RemeGen. Started Mar 2021; status: completed.
02
Drugs
eflimrufusp alfa
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04782115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782115.